Miajas, Rolando A.

HRN: 22-97-97  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/03/2023
CO-AMOXICLAV 625MG (TAB)
05/03/2023
05/10/2023
PO
625mg
BID
Exfoliative Dermatitis Superimposed With Bacterial Infection
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: